HIGHLIGHTS
- who: Diego Carbonell et al. from the Department of Hematology, Gregorio Marañón General University Hospital, Madrid, Spain have published the paper: FLT3-ITD Expression as a Potential Biomarker for the Assessment of Treatment Response in Patients with Acute Myeloid Leukemia, in the Journal: Cancers 2022, 4006 of /2022/
- what: The aims of this study were to compare FLT3-ITD mutation analysis in DNA and cDNA samples at diagnosis and to demonstrate the usefulness of its measurement an MRD marker after allogeneic stem cell transplantation (allo-HSCT) or FLT3 inhibitor (FLT3i) administration. total of 46 . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.